Marcial: BioSante May Be Buyout Bait

The biotech's LibiGel, in clinical trials, could make it a player in treating female sexual dysfunctionand draw bids from Big Pharma

BioSante Parmaceuticals (BPAX) is going where Procter & Gamble (PG) and Pfizer (PFE) feared to tread: developing products aimed at restoring the loss of sexual desire in women. The little-known Lincolnshire (Ill.) biotech is developing hormone replacement products to treat testosterone deficiency in men and estrogen deficiency in women. But its lead product, LibiGel, is what's attracting investor attention.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.